32.25
-0.35(-1.07%)
Currency In CNY
Sector
Healthcare
Industry
Biotechnology
Employees
1407
First IPO Date
December 14, 2020
| Name | Title | Pay | Year Born |
| Mr. Yanqing Zhao | Chief Executive Officer, GM & Director | 0 | 1982 |
| Ms. Xiaoqin Wang | Chief Financial Officer, Secretary to the Board & Director | 0 | 1977 |
| Ms. Hongjie Ma | Deputy GM & GM of Technology Center | 0 | 1971 |
| Ms. Ning Cui | Deputy GM & Director | 0 | 1977 |
| Mr. Ke Shao | Deputy General Manager | 0 | 1971 |
| Mr. Suofu Qin | Deputy General Manager | 0 | 1964 |
Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. The company focuses on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunity, blood, digestion, and degenerative diseases. Its products include recombinant human interferon a1b, human erythropoietin, and human granulocyte stimulating factor; Clostridium butyricum combined live bacteria powder; Kehuang Capsule, a Chinese patent medicine; Entecavir, a chemical drug; and liraglutide, a human glucagon-like peptide-1, as well as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. The company was founded in 1989 and is based in Jinan, China.
